People: Abaxis Inc (ABAX.O)
25 May 2017
Mr. Michael D. Casey is an Independent Director of the company. Mr. Casey is currently retired. Mr. Casey has served on the Board of Directors of Celgene Corporation (NASDAQ: CELG) since 2002. From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. (NYSE: SHP). In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey previously served on the Board of Directors of AVI Biopharma, Inc (now known as Sarepta Therapeutics, Inc.) from 2006 to 2010, Allos Therapeutics, Inc. (NASDAQ: ALTH) from 2002 to 2010, Cholestech Corporation from 2001 to 2007, OrthoLogic Corporation (NASDAQ: OLGC) from 2004 to 2007, Sicor, Inc. (NASDAQ: SCRI) from 2002 to 2004, Bone Care International, Inc. (NASDAQ: BCII) from 2001 to 2005 and Durect Corp. (NASDAQ: DRRX) from 2004 to 2013. Mr. Casey was selected to serve as director because of his extensive industry knowledge and experience, including operational, leadership and board experience from his executive positions at pharmaceutical/biotechnology companies.
|Total Annual Compensation, USD||26,250|
|Restricted Stock Awards, USD||275,400|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||--|
|Fiscal Year Total, USD||301,650|